• 한국식품영양학회지
• /
• 제28권6호
• /
• pp.941-946
• /
• 2015

본 연구에서는 HA에 대하여 UVB로 주름을 유도시킨 hairless mice에게 경구 투여를 하였을 때, 주름 개선에 미치는 영향을 관찰하였다. 쥐는 UV를 쪼여 광노화를 진행하였으며, HA는 UVB에 노출시키기 4주 전부터 투여하여 총 14주 동안 투여하였다. 주름 개선 평가는 replica 제작하여 주름의 길이, 깊이, 개수, 두께로 평가하였다. 또한, 피부의 조직학적 평가를 통해 진피층 내 교원섬유와 탄력섬유의 양과 형태를 관찰하였다. 10주 동안의 HA를 급여하였을 때 주름의 깊이, 두께, 개수를 측정한 주름 개선 평가에서 세 항목 모두 개선되는 결과를 보였다. 특히 HA의 160 mg/kg 농도에서는 주름의 깊이는 $19.44{\pm}0.75{\mu}m$, 주름 수는 $654.00{\pm}98.34$, 주름두께는 $1.35{\pm}0.08mm$로 양성 대조군(RA)의 결과(주름깊이; $19.28{\pm}0.95{\mu}m$, 주름 수; $953.57{\pm}83.54$, 주름두께; $1.34{\pm}0.07mm$)와 비슷한 수치를 나타내며, 우수한 피부 광노화 개선효과를 보였다. 하지만, 주름길이의 결과에서는 유의적 차이를 나타내지 않았다. HA의 섭취로 인한 교원섬유 및 탄력섬유 염색을 통한 조직학적 평가에서는 UV에 의해 밀도가 엉성하고 배열이 불규칙적이던 섬유들이 개선된 것을 관찰할 수 있었다. 이상의 결과로 보아 HA를 경구 투여 시 UV로부터 유도된 광노화 억제 및 피부주름 개선에 효능이 있음을 확인하였다.

• 분석과학
• /
• 제28권2호
• /
• pp.132-138
• /
• 2015

Rosiglitazone metabolites in rat plasma were analyzed after intraperitoneal and oral administration to rats. Seven metabolites (M1-M7) were detected in rat plasma (IP and PO), and the structures were confirmed using liquid chromatography-triple time of flight (TOF) mass spectrometry; as a result, the most abundant metabolite was M5, a de-methylated rosiglitazone. Other minor in vivo metabolites were driven from monooxygenation and demethylation (M2), thiazolidinedione ring-opening (M1, M3), mono-oxygenation (M4, M7), and mono-oxygenation followed by sulfation (M6). Among them, M1 was found to be a 3-{p-[2-(N-methyl-N-2-pyridylamino)ethoxy]phenyl}-2-(methylsulfinyl)propionamide, which is a novel metabolite of rosiglitazone. There was no significant difference in the metabolic profiles resulting from the two administrations. The findings of this study provide the first comparison of circulating metabolite profiles of rosiglitazone in rat after IP and PO administration and a novel metabolite of rosiglitazone in rat plasma.

• Toxicological Research
• /
• 제30권2호
• /
• pp.121-130
• /
• 2014

The larval form of Tenebrio molitor (T. molitor) has been eaten in many countries and provides benefits as a new food source of protein for humans. However, no information exists regarding its safety for humans. The objective of the present study was to evaluate the genotoxicity and repeated dose oral toxicity of the freeze-dried powder of T. molitor larvae. The genotoxic potential was evaluated by a standard battery testing: bacterial reverse mutation test, in vitro chromosome aberration test, and in vivo micronucleus test. To assess the repeated dose toxicity, the powder was administered once daily by oral gavage to Sprague-Dawley (SD) rats at dose levels of 0, 300, 1000 and 3000 mg/kg/day for 28 days. The parameters which were applied to the study were mortality, clinical signs, body and organ weights, food consumption, ophthalmology, urinalysis, hematology, serum chemistry, gross findings and histopathologic examination. The freezedried powder of T. molitor larvae was not mutagenic or clastogenic based on results of in vitro and in vivo genotoxicity assays. Furthermore, no treatment-related changes or findings were observed in any parameters in rats after 28 days oral administration. In conclusion, the freeze-dried powder of T. molitor larvae was considered to be non-genotoxic and the NOAEL (No Observed Adverse Effect Level) was determined to be 3000 mg/kg/day in both sexes of SD rats under our experimental conditions.

• Archives of Pharmacal Research
• /
• 제29권4호
• /
• pp.318-322
• /
• 2006

Many quaternary ammonium salts are incompletely absorbed after their oral administration and may also be actively secreted into the intestine. However, the underlying mechanism(s) that control the transport of these cations across the intestinal epithelium is not well understood. In this study, the mechanism of absorption of quaternary ammonium salts was investigated using Caco-2 cell monolayers, a human colon carcinoma cell line. Tributylmethylammonium (TBuMA) was used as a model quaternary ammonium salts. When TBuMA was administrated at a dose of 13.3 imole/kg via iv and oral routes, the AUC values were $783.7{\pm}43.6\;and\;249.1{\pm}28.0{\mu}mole\;min/L$ for iv and oral administration, indicating a lower oral bioavailability of TBuMA $(35.6\%)$. The apparent permeability across Caco-2 monolayers from the basal to the apical side was 1.3 times (p<0.05) greater than that from the apical to the basal side, indicating a net secretion of TBuMA in the intestine. This secretion appeared to be responsible for the low oral bioavailability of the compound, probably mediated by p-gp (p-glycoprotein) located in the apical membrane. In addition, the uptake of TBuMA by the apical membrane showed a $Na^+$ dependency. Thus, TBuMA appears to absorbed via a $Na^+$ dependent carrier and is then secreted via p-gp related carriers.

• 한국어병학회지
• /
• 제31권1호
• /
• pp.23-34
• /
• 2018

세파드록실 (CDX)의 수온에 따른 잔류 약동학적 특성을 알아보기 위해 평균 660 g의 넙치를 비교수온 ($13{\pm}3^{\circ}C$) 및 적정수온 ($22{\pm}3^{\circ}C$)에서 7일간 임상용량 (45 mg/kg b.w.)과 임상용량의 5배에 해당하는 양 (225 mg/kg b.w.)으로 연속 경구투여 후 시간에 따른 근육, 혈장, 위-장관, 조혈조직 (신장+비장) 및 간장에서 잔류농도를 HPLC-MS/MS로 분석하였다. CDX의 농도 측정을 위해 근육에서는 투여종료 후 0.25, 0.5, 1, 3, 7, 14 및 28일에 분석하였고, 혈장, 위-장관, 조혈조직 및 간장에서는 1, 3, 7, 14 및 28일에 분석하였다. 경시적 잔류농도를 바탕으로 PKSolver program의 non-compartmental model로 최고농도 ($C_{max}$), 최고농도 도달시간 ($T_{max}$), 배설반감기 ($T_{1/2}$) 등의 약물동태학적 매개변수(parameter)를 계산하였다. 근육, 혈장, 위-장관, 조혈조직 및 간장에서 최고농도 및 최고농도 도달시간은 각각 $985.98-5,032.86{\mu}g/kg$ (1일), $5,670.99-38,922.23{\mu}g/l$ (1일), $2,457.27-10,192.78{\mu}g/kg$ (1일), $886.04-3,070.87{\mu}g/kg$ (1일) 및 $1,188.15-3,814.33{\mu}g/kg$ (1일)으로 계산되었다. 평균체류시간 ($MRT_{0-{\infty}}$)과 배설반감기 ($T_{1/2}$)는 각각 1.51-4.74일 (1.08-3.47일), 2.12-3.06 (1.14-5.42일), 4.25-13.18일 (3.56-10.99일), 1.37-18.66일 (1.17-14.93일) 및 1.78-29.76일 (1.25-28.55일)로 계산되었다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제33권4호
• /
• pp.670-677
• /
• 2020

Objective: Interleukin-6 (IL-6) is a T cell-derived B cell stimulating factor which plays an important role in inflammatory diseases. In this study, the pharmacokinetic properties of LMT-28 including physicochemical property, in vitro liver microsomal stability and an in vivo pharmacokinetic study using BALB/c mice were characterized. Methods: LMT-28 has been synthesized and is being developed as a novel therapeutic IL-6 inhibitor. The physicochemical properties and in vitro pharmacokinetic profiles such as liver microsomal stability and Madin-Darby canine kidney (MDCK) cell permeability assay were examined. For in vivo pharmacokinetic studies, pharmacokinetic parameters using BALB/c mice were calculated. Results: The logarithm of the partition coefficient value (LogP; 3.65) and the apparent permeability coefficient values (P_app; 9.7×10^-6 cm/s) showed that LMT-28 possesses a moderate-high cell permeability property across MDCK cell monolayers. The plasma protein binding rate of LMT-28 was 92.4% and mostly bound to serum albumin. The metabolic half-life (t_1/2) values of LMT-28 were 15.3 min for rat and 21.9 min for human at the concentration 1 μM. The area under the plasma drug concentration-time curve and C_max after oral administration (5 mg/kg) of LMT-28 were 302±209 h·ng/mL and 137±100 ng/mL, respectively. Conclusion: These data suggest that LMT-28 may have good physicochemical and pharmacokinetic properties and may be a novel oral drug candidate as the first synthetic IL-6 inhibitor to ameliorate mammalian inflammation.

• 대한한의학방제학회지
• /
• 제31권1호
• /
• pp.21-28
• /
• 2023

Objective : Scolopendra, a dried body of Scolopendra subspinipes mutilans, is one of Korean medicine. Several reports revealed that Scolopendra has therapeutic effects for arthritis, neuroinflammatory diseases and neuropathic pain. However, the fetal adaptive response or teratogenicity associated with administration of Scolopendra is unclear. Therefore, this study aimed to investigate the fetal toxicity effects that were induced following oral administration of Scolopendra water extract (SWE) in pregnant mice. Methods : The pregnant mice were administrated SWE at dosed of 0, 100, 500 and 1000 mg/kg/day during gestation day 0-18. The mortality, body weight and clinical signs of pregnant mice were observed throughout experimental period. Also, the mortality and malformations in foetus were examined. Results : No meaningful changes were observed in the mortality and clinical signs of pregnant mice between the normal control group and SWE administrated groups. Additionally, there are no significant changes in fetal mortalities, and malformations by SWE administration. conclusion : These results suggest that oral exposure to SWE during pregnancy at oral dosages up to 1000 mg/kg/day did not induce teratogenic toxicity in regard to fetal mortality and morphology.

• 대한한방내과학회지
• /
• 제34권4호
• /
• pp.349-361
• /
• 2013

Objectives : This study aimed to evaluate the single oral dose toxicity and four weeks repeated dose determination of Gamisasangja-tang (GST) in male and female Sprague-Dawley rats. Methods : In the single oral toxicity study, rats were orally administered a single dose of 0 and 5,000 mg/kg GST. There were 5 rats in each group. After single administration, mortality, clinical signs, body weight changes and gross pathological finding were observed for 14 days. In the 4-weeks repeated oral dose determination study, rats were orally administered a single dose of 0, 1,250, 2,500 or 5,000 mg/kg GST. There were 5 rats in each group. Mortality, clinical signs, body weight changes, food consumption and gross pathological finding were observed for 28 days. Organ weight, clinical chemistry and hematology were tested after 28 days. Results : There was no mortality in either of the two studies. There were also no significant differences in clinical sign, body weight, organ weights, hematological or serum chemical parameters between the GST and control groups. Conclusions : The results obtained in this study suggest that the 50% lethal dose of GST is over 5,000 mg/kg, so this finding would be expected to provide scientific evidence for the safety of GST.

• Toxicological Research
• /
• 제28권1호
• /
• pp.11-18
• /
• 2012

The aim of this study was to evaluate the single oral dose toxicity of Bupleuri Radix (BR) aqueous extracts, it has been traditionally used as anti-inflammatory agent, in male and female mice. BR extracts (yield = 16.52%) was administered to female and male ICR mice as an oral dose of 2,000, 1,000 and 500 mg/kg (body weight) according to the recommendation of Korea Food and Drug Administration (KFDA) Guidelines. Animals were monitored for the mortality and changes in body weight, clinical signs and gross observation during 14 days after dosing, upon necropsy; organ weight and histopathology of 14 principal organs were examined. As the results, no BR extracts treatment related mortalities, clinical signs, changes on the body and organ weights, gross and histopathological observations against 14 principal organs were detected up to 2,000 mg/kg in both female and male mice, except for soft feces and related body weight decrease detected in male mice treated with 2,000 mg/kg. Therefore, $LD_{50}$ (50% lethal dose) and approximate LD of BR aqueous extracts after single oral treatment in female and male mice were considered over 2000 mg/kg, respectively. Although it was also observed that the possibilities of digestive disorders, like soft feces when administered over 2,000 mg/kg of BR extracts in the present study, these possibilities of digestive disorders can be disregard in clinical use because they are transient in the highest dosages male only.

• 수산해양교육연구
• /
• 제28권3호
• /
• pp.692-700
• /
• 2016

넙치($700{\pm}50g$, $23{\pm}1.5^{\circ}C$) 및 조피볼락($500{\pm}30g$, $23{\pm}1.5^{\circ}C$)에게 Thiamphenicol(TP)을 1일 1회 경구(100 mg/kg BW) 투여한 다음, 경시적(1시간~432시간)으로 혈청 내 TP의 잔류량을 HPLC로써 분석하였다. TP를 어류 혈청에 0.1, 1.0, $10{\mu}g/mL$으로 첨가한 각각의 농도에 대하여 넙치 및 조피볼락에서 TP의 평균 회수율은 77.05~97.23%와 89.96~97.11%로 나타났다. TP의 경구 투여에 따른 넙치와 조피볼락의 체내 약물 혈중농도는 two-compartment model로 조사되었다. TP를 투여 후 넙치 혈청에서 10시간째 $10.08{\mu}g/mL$와 15시간째 $10.06{\mu}g/mL$로 최대값을 보였고, 조피볼락 혈청에서는 15시간째 $8.88{\mu}g/mL$로 최대값을 나타내었다. 넙치와 조피볼락의 혈청에서 TP는 투여 후 432시간째(18일째) 모든 시료에서 검출한계 이하로 검출되지 않았다. TP의 어류 체내 잔류 양상은 넙치와 조피볼락에서 매우 유사하였다. 본 연구에서 얻어진 결과는 넙치와 조피볼락에 TP를 처방하여 치료 계획을 수립할 때 유용하게 활용될 것으로 여겨진다.